Laboratory-based non-clinical comparison of occlusion rates using three rapid-acting insulin analogs in continuous subcutaneous insulin infusion catheters using low flow rates

Journal of Diabetes Science and Technology

Volumn 2, Issue 3, 2008, Pages 450-455

  Kerr, David ^a,c   Morton, John ^a   Whately Smith, Caroline ^b   Everett, Joan ^a   Begley, Joe P ^a,c  

^a ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^b Whately Smith Ltd   (United Kingdom)

^c BOURNEMOUTH UNIVERSITY   (United Kingdom)

Author keywords

Analogs; CSII; Insulin; Occlusions; Temperature

Indexed keywords

EID: 77956139107     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229680800200314     Document Type: Article

References (11)

1. NICE Technology Appraisal Guidance No. 57: Guidance on the use of continuous subcutaneous insulin infusion for diabetes. National Institute for Clinical Excellence. February 2003.
2. Plank J, Siebenhofer A, Berghold A, Jeitler K, Horvath K, Mrak P, Pieber TR. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med. 2005;165(12):1337-44.
3. Medtronic Diabetes UK [homepage on the Internet]. Watford UK: Medtronic MiniMed, Inc.; 2008 [cited 2007 September 30]. Effective infusion site management. Available from: http://www.medtronic-diabetes.co.uk/pdf/MedtronicUK/ .
4. Guilhem I, Leguerrier AM, Lecordier F, Poirier JY, Maugendre D. Technical risks with subcutaneous insulin infusion. Diabetes Metab. 2006;32(3):279-84.
5. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care. 2003;26(4):1079-87.
6. Bode B, Weinstein R, Bell D, McGill J, Nadeau D, Raskin P, Davidson J, Henry R, Huang W, Reinhardt RR. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes. Diabetes Care. 2002;25(3):439-44
7. Wolpert HA, Faradji RN, Bonner-Weir S, Lipes MA. Metabolic decompensation in pump users due to lispro insulin precipitation. BMJ. 2002;324(7348):1253.
8. Hoogma R P, Schumicki D. Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes. Horm Metab Res. 2006;38(6):429-33.
9. De Felippis MR, Bell MA, Heyob JA, Storms SM. In vitro stability of insulin lispro in continuous subcutaneous insulin infusion. Diabetes Technol Ther. 2006;8(3):358-68.
10. Senstius J, Harboe E, Westermann H. In vitro stability of insulin aspart in simulated continuous subcutaneous insulin infusion using a MiniMed 508 insulin pump. Diabetes Technol Ther. 2007;9(1):75-9.
11. Brange J, Andersen L, Laursen ED, Meyn G, Rasmussen E. Toward understanding insulin fbrillation. J Pharma Sci. 1997;86(5):517-25.